← Back to patent-cliff list
RBD-1006
Tier C — Watch / tradeRBD-1006
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AR
Indications (approved)：Castration-resistant prostate cancer
Regional status
US
-
EU
-
China
Phase II
2024-12-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RBD-1006?
Approved indications include: Castration-resistant prostate cancer.
When does the RBD-1006 patent expire?
No public expiry year is available for RBD-1006 yet; this page updates once verified.
How do I get a quote for RBD-1006 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01